Recombinant Human Prolactin for Lactation Induction

December 8, 2017 updated by: Corrine Welt, Massachusetts General Hospital

Recombinant Human Prolactin for Lactation Induction in Prolactin Deficient Mothers

The purpose of the study is to assess the safety and determine the effects of the hormone prolactin on lactation (breast milk production).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The efficacy of recombinant human prolactin (r-hPRL) for treatment of primary lactation insufficiency in women with prolactin deficiency, either congenital or acquired, will be examined. Subjects will participate in an open-label study of r-hPRL administration for prolactin deficiency. On study day 1, subjects will be seen between 8 and 10 am. A baseline prolactin level will be obtained. Subjects will subsequently be taught to use a breast pump by a designated lactation consultant and will pump for 10 minutes at each breast, simultaneously or sequentially. Any milk production will be recorded, along with milk volume throughout the study. Prolactin levels will be obtained every 10 minutes for 60 minutes after pumping begins, then every 30 minutes for a total of 3 hours. At 3 hours, r-hPRL 60 mg/kg will be administered SC. Blood will be drawn every 2 hours for 8 hours to obtain a peak prolactin level. Vital signs will be monitored every 15 minutes for the first hour, then every 2 hours for a total of 8 hours. Subjects will again pump both breasts 0, 3 and 6 hours after the r-hPRL injection, to maintain an every 3 hour schedule. Any milk production will be recorded. Subjects will administer their second dose of SC r-hPRL 12 hours after the first dose.

Subjects will continue every 12 hour SC r-hPRL administration for the next 28 days. They will also pump every 3 hours, with the exception of a 5 hour break for sleep at one time during the 24 hours, as long as the total number of pumping episodes equals 8. Subjects will record any milk production and will call as soon as any milk is expressed. When the first milk is produced, the infant will not be allowed to suckle at the breast until the milk is tested and readministered to the infant in a controlled setting to avoid any potential risks or r-hPRL exposure to the infant in the interim. After each pumping episode, if no milk is produced mothers will be encouraged to let their infants feed at the breast using a Lact-Aid device.

Subjects will be seen in the GCRC, weekly for 28 days. At each visit, subjects will have a breast exam for galactorrhea and a baseline prolactin level, then subjects will administer their own SC r-hPRL injection and pump at 0, 3 and 6 hours after r-hPRL administration, as described above. Any milk production will be recorded. In addition, at the end of week 1 and on the final day, r-hPRL will be administered, blood will be drawn every 2 hours for prolactin levels as on the first day of the injection, for a total of 8 hours, and subjects will pump and milk volume will be recorded at 0, 3 and 6 hours after r-hPRL administration.

When at least 0.25 cc of milk is produced by pumping, it will be sent for a prolactin level measurement to determine whether levels are elevated compared to levels in the control milk. If the prolactin level is not elevated, milk will be readministered to the infant. When breast milk is first given to the infants, they will be monitored in the GCRC under the supervision of a neonatologist, with vital signs, including temperature, measured every hour after feeding for 4 hours. The mother will also record stool and gastric output and any changes noted in the quality or quantity of output for the following 24 hours. If any significant and adverse changes in vital signs or gastric output are observed, any additional stored breast milk will be discarded and the study stopped. After the prolactin level in milk has been documented in the normal range and milk readministered to the infant under supervision in the GCRC, mothers will continue to pump immediately after the am r-hPRL dose, but at all other times will be encouraged to breastfeed.

When at least 1 cc of milk is available, milk composition will also be analyzed for fat, protein, glucose, lactose and IgA levels (see Procedure for Analyzing Collected Milk, above). Studies in mothers of premature infants will be performed before starting this protocol. If the level of any of these components is 50% below the lower limit of normal, breast milk will be supplemented with formula at a ratio determined by the neonatologist to ensure that all nutrients are received.

After completing 28 days of every 12 hour r-hPRL administration, breast milk production will continue to be monitored for a 14 day control period. Subjects will be seen at 7 and 14 days after their final prolactin injection. After a baseline prolactin level is drawn, milk will be pumped until the breasts are emptied. Blood will be drawn at baseline and then every 10 minutes for 60 minutes, then every 30 minutes for a total of 3 hours to obtain a prolactin peak.

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Healthy women, aged 18-45 years
  • Prolactin deficiency due to congenital deficiency, surgery or radiation, or Sheehan's syndrome during the current or previous pregnancies, for women who desire to breastfeed their infants.
  • Postpartum at the time of study participation
  • Milk must fail to come in by 2-4 days after delivery.
  • Prolactin levels will be less than the lower limit of normal for the assay performed. If a subject is postpartum, prolactin levels will be less than the normal range for postpartum women (<= 138.0 ± 11.9 ng/mL).
  • Free T4 index must be normal either on or off thyroid hormone replacement.
  • Fasting am cortisol or 1 hour Cortrosyn 0.25 mg stimulated cortisol must be normal (>18 mg/dL). If it is not normal, subjects must be on glucocorticoid replacement and have no symptoms of adrenal insufficiency.
  • History of normal spontaneous puberty or Tanner stage V breast development after previous estrogen replacement therapy.

Exclusion Criteria:

  • Current use of medications known to increase or decrease prolactin
  • Anatomical breast abnormalities
  • Previous mammoplasty
  • Breast augmentation
  • Current use of hormonal contraception
  • Allergies to mannitol
  • Medications contraindicated for breastfeeding mothers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: recombinant human prolactin treatment
Open label twice daily recombinant human prolactin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Breast Milk Production
Time Frame: 28 days
Treatment group
28 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Breast Milk Prolactin Levels
Time Frame: 28 days
Treatment group
28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2005

Primary Completion (Actual)

May 1, 2011

Study Completion (Actual)

May 1, 2011

Study Registration Dates

First Submitted

September 9, 2005

First Submitted That Met QC Criteria

September 9, 2005

First Posted (Estimate)

September 16, 2005

Study Record Updates

Last Update Posted (Actual)

December 11, 2017

Last Update Submitted That Met QC Criteria

December 8, 2017

Last Verified

December 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 2003P001209-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe